CervoMed (CRVO) announced that its oral investigational drug neflamapimod has been granted Orphan Drug Designation, ODD, by the U.S. Food and Drug Administration, FDA, for the treatment of frontotemporal dementia, FTD. “We are pleased to have received Orphan Drug Designation as it implicitly recognizes the scientific rationale and potential for neflamapimod to treat this debilitating condition. Patients diagnosed with frontotemporal dementia have no available treatment options, and this rare condition is extremely burdensome to patients and caregivers alike,” said John Alam, MD, Chief Executive Officer of CervoMed. “Within this year, there have been multiple scientific presentations and publications that indicate neflamapimod targets specific pathogenic mechanisms associated with FTD. We are in active discussions with clinical thought leaders regarding the design of a proof-of-principle study in FTD, while continuing to prepare to advance neflamapimod into a Phase 3 trial in DLB in mid-2025.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRVO:
- CervoMed initiated with a Buy at D. Boral Capital
- CervoMed appoints Ordonez, Rosch as SVPs
- CervoMed Inc. Reports Increased R&D Expenses Amid Ongoing Trials
- CervoMed reports Q3 EPS (55c), consensus (41c)
- CRVO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
